Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US29479A1088
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00MTSR883
ERAS
Erasca Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Erasca Inc
ISIN
US29479A1088
TICKER
ERAS
MIC
XNAS
REUTERS
ERAS.OQ
BLOOMBERG
ERAS US
Fri, 15.05.2026       Erasca
US29479A1088

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Erasca
US29479A1088

The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Erasca
US29479A1088

ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Erasca
US29479A1088

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Erasca
US29479A1088

Boston, Massachusetts--(Newsfile Corp. - May 1, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Erasca
US29479A1088

Boston, Massachusetts--(Newsfile Corp. - April 29, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blocklevi...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.04.2026       Erasca
US29479A1088

Conference call and live webcast today at 4:30 PM Eastern Time Conference call and live webcast today at 4:30 PM Eastern Time...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Erasca
US29479A1088

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shar...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. Th...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 20.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 mill...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.01.2026       Erasca
US29479A1088

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /CNW/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a loomin...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.01.2026       Erasca
US29479A1088

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.01.2026       Erasca
US29479A1088

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Erasca
US29479A1088

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total can...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Erasca
US29479A1088

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /CNW/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer dru...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.11.2025       Erasca
US29479A1088

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the L...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       Erasca
US29479A1088

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Erasca
US29479A1088

Early entry of RAS-targeting franchise into clinic enabled by strong execution...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.03.2025       Erasca
US29479A1088

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 20.03.2025       Erasca
US29479A1088

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.01.2025       Erasca
US29479A1088

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.11.2024       Erasca
US29479A1088

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also p...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.05.2024       Erasca
US29479A1088

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.05.2024       Erasca
US29479A1088

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a p...
Read more
Erasca
Technical Analysis Termsheets Terminal
Permalink